 | • レポートコード：GIR-22F19276 • 出版社/出版日：GlobalInfoResearch / 2022年11月 • レポート形態：英文、PDF、106ページ • 納品方法：Eメール（2~3営業日） • 産業分類：医薬品 |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 「Global Drugs for Retroperitoneal Fibrosis Market 2022」レポートは、世界の市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。 グローバルインフォリサーチ社の最新の調査によると、世界の後腹膜線維症治療薬の市場規模は2021年のxxx米ドルから2028年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。 後腹膜線維症治療薬市場はタイプ（種類）とアプリケーション（用途）によって区分されます。2017年～2028年において、量と金額の観点からタイプ別およびアプリケーション別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。 タイプ別セグメントは次をカバーします。 ・コルチコステロイド、免疫抑制剤 アプリケーション別セグメントは次のように区分されます。 ・病院調剤薬局、小売調剤薬局、オンライン調剤薬局、その他 世界の後腹膜線維症治療薬市場の主要な市場プレーヤーは以下のとおりです。 ・AstraZeneca Pharmaceuticals、Eli Lilly、GlaxoSmithKline、Abbott、Johnson & Johnson、Sanofi、Pfizer、Merck、Bayer、Novartis 地域別セグメントは次の地域・国をカバーします。 ・北米市場（米国、カナダ、メキシコ） ・ヨーロッパ市場（ドイツ、フランス、イギリス、ロシア、イタリア） ・アジア太平洋市場（日本、中国、韓国、インド、東南アジア、オーストラリア） ・南米市場（ブラジル、アルゼンチン、コロンビア） ・中東・アフリカ市場（サウジアラビア、UAE、エジプト、南アフリカ） 本調査レポートの内容は計15章あります。 ・第1章では、後腹膜線維症治療薬製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。 ・第2章では、主要な後腹膜線維症治療薬メーカーの企業概要、2019年～2022年までの後腹膜線維症治療薬の価格、販売量、売上、市場シェアを掲載しています。 ・第3章では、主要な後腹膜線維症治療薬メーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。 ・第4章では、2017年～2028年までの地域別後腹膜線維症治療薬の販売量、売上、成長性を示しています。 ・第5、6章では、2017年～2028年までの後腹膜線維症治療薬のタイプ別とアプリケーション別の市場規模、市場シェアと成長率を掲載しています。 ・第7、8、9、10、11章では、2017年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2028年までの主要地域での後腹膜線維症治療薬市場予測を収録しています。 ・第12章では、主要な原材料、主要なサプライヤー、および後腹膜線維症治療薬の産業チェーンを掲載しています。 ・第13、14、15章では、後腹膜線維症治療薬の販売チャネル、販売業者、顧客、調査結果と結論、付録、データソースなどについて説明します。 ***** 目次(一部) ***** ・市場概要 - 後腹膜線維症治療薬の概要 - タイプ別分析（2017年vs2021年vs2028年）：コルチコステロイド、免疫抑制剤 - アプリケーション別分析（2017年vs2021年vs2028年）：病院調剤薬局、小売調剤薬局、オンライン調剤薬局、その他 - 世界の後腹膜線維症治療薬市場規模・予測 - 世界の後腹膜線維症治療薬生産能力分析 - 市場の成長要因・阻害要因・動向 ・メーカー情報（企業概要、製品概要、販売量、価格、売上） - AstraZeneca Pharmaceuticals、Eli Lilly、GlaxoSmithKline、Abbott、Johnson & Johnson、Sanofi、Pfizer、Merck、Bayer、Novartis ・メーカー別市場シェア・市場集中度 ・地域別市場分析2017年-2028年 ・タイプ別分析2017年-2028年：コルチコステロイド、免疫抑制剤 ・アプリケーション別分析2017年-2028年：病院調剤薬局、小売調剤薬局、オンライン調剤薬局、その他 ・後腹膜線維症治療薬の北米市場分析 - 後腹膜線維症治療薬の北米市場：タイプ別市場規模2017年-2028年 - 後腹膜線維症治療薬の北米市場：アプリケーション別市場規模2017年-2028年 - 主要国別市場規模：アメリカ、カナダ、メキシコなど ・後腹膜線維症治療薬のヨーロッパ市場分析 - ：後腹膜線維症治療薬のヨーロッパ市場：タイプ別市場規模2017年-2028年 - ：後腹膜線維症治療薬のヨーロッパ市場：アプリケーション別市場規模2017年-2028年 - 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど ・後腹膜線維症治療薬のアジア太平洋市場分析 - 後腹膜線維症治療薬のアジア太平洋市場：タイプ別市場規模2017年-2028年 - 後腹膜線維症治療薬のアジア太平洋市場：アプリケーション別市場規模2017年-2028年 - 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど ・後腹膜線維症治療薬の南米市場分析 - 後腹膜線維症治療薬の南米市場：タイプ別市場規模2017年-2028年 - 後腹膜線維症治療薬の南米市場：アプリケーション別市場規模2017年-2028年 - 主要国別市場規模：ブラジル、アルゼンチンなど ・後腹膜線維症治療薬の中東・アフリカ市場分析 - 後腹膜線維症治療薬の中東・アフリカ市場：タイプ別市場規模2017年-2028年 - 後腹膜線維症治療薬の中東・アフリカ市場：アプリケーション別市場規模2017年-2028年 - 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど ・原材料および産業チェーン ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Drugs for Retroperitoneal Fibrosis market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Drugs for Retroperitoneal Fibrosis market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during forecast period 2022-2028. Hospital Pharmacy accounting for % of the Drugs for Retroperitoneal Fibrosis global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Corticosteroids segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Drugs for Retroperitoneal Fibrosis include AstraZeneca Pharmaceuticals, Eli Lilly, GlaxoSmithKline, Abbott, and Johnson & Johnson, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Drugs for Retroperitoneal Fibrosis market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Corticosteroids
Immunosuppressant
Market segment by Application can be divided into
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Other
The key market players for global Drugs for Retroperitoneal Fibrosis market are listed below:
AstraZeneca Pharmaceuticals
Eli Lilly
GlaxoSmithKline
Abbott
Johnson & Johnson
Sanofi
Pfizer
Merck
Bayer
Novartis
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Drugs for Retroperitoneal Fibrosis product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Drugs for Retroperitoneal Fibrosis, with price, sales, revenue and global market share of Drugs for Retroperitoneal Fibrosis from 2019 to 2022.
Chapter 3, the Drugs for Retroperitoneal Fibrosis competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Drugs for Retroperitoneal Fibrosis breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Drugs for Retroperitoneal Fibrosis market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Drugs for Retroperitoneal Fibrosis.
Chapter 13, 14, and 15, to describe Drugs for Retroperitoneal Fibrosis sales channel, distributors, customers, research findings and conclusion, appendix and data source.
1 Market Overview
1.1 Drugs for Retroperitoneal Fibrosis Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Drugs for Retroperitoneal Fibrosis Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 Corticosteroids
1.2.3 Immunosuppressant
1.3 Market Analysis by Application
1.3.1 Overview: Global Drugs for Retroperitoneal Fibrosis Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Hospital Pharmacy
1.3.3 Retail Pharmacy
1.3.4 Online Pharmacy
1.3.5 Other
1.4 Global Drugs for Retroperitoneal Fibrosis Market Size & Forecast
1.4.1 Global Drugs for Retroperitoneal Fibrosis Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Drugs for Retroperitoneal Fibrosis Sales in Volume (2017-2028)
1.4.3 Global Drugs for Retroperitoneal Fibrosis Price (2017-2028)
1.5 Global Drugs for Retroperitoneal Fibrosis Production Capacity Analysis
1.5.1 Global Drugs for Retroperitoneal Fibrosis Total Production Capacity (2017-2028)
1.5.2 Global Drugs for Retroperitoneal Fibrosis Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Drugs for Retroperitoneal Fibrosis Market Drivers
1.6.2 Drugs for Retroperitoneal Fibrosis Market Restraints
1.6.3 Drugs for Retroperitoneal Fibrosis Trends Analysis
2 Manufacturers Profiles
2.1 AstraZeneca Pharmaceuticals
2.1.1 AstraZeneca Pharmaceuticals Details
2.1.2 AstraZeneca Pharmaceuticals Major Business
2.1.3 AstraZeneca Pharmaceuticals Drugs for Retroperitoneal Fibrosis Product and Services
2.1.4 AstraZeneca Pharmaceuticals Drugs for Retroperitoneal Fibrosis Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 Eli Lilly
2.2.1 Eli Lilly Details
2.2.2 Eli Lilly Major Business
2.2.3 Eli Lilly Drugs for Retroperitoneal Fibrosis Product and Services
2.2.4 Eli Lilly Drugs for Retroperitoneal Fibrosis Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 GlaxoSmithKline
2.3.1 GlaxoSmithKline Details
2.3.2 GlaxoSmithKline Major Business
2.3.3 GlaxoSmithKline Drugs for Retroperitoneal Fibrosis Product and Services
2.3.4 GlaxoSmithKline Drugs for Retroperitoneal Fibrosis Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 Abbott
2.4.1 Abbott Details
2.4.2 Abbott Major Business
2.4.3 Abbott Drugs for Retroperitoneal Fibrosis Product and Services
2.4.4 Abbott Drugs for Retroperitoneal Fibrosis Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 Johnson & Johnson
2.5.1 Johnson & Johnson Details
2.5.2 Johnson & Johnson Major Business
2.5.3 Johnson & Johnson Drugs for Retroperitoneal Fibrosis Product and Services
2.5.4 Johnson & Johnson Drugs for Retroperitoneal Fibrosis Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6 Sanofi
2.6.1 Sanofi Details
2.6.2 Sanofi Major Business
2.6.3 Sanofi Drugs for Retroperitoneal Fibrosis Product and Services
2.6.4 Sanofi Drugs for Retroperitoneal Fibrosis Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7 Pfizer
2.7.1 Pfizer Details
2.7.2 Pfizer Major Business
2.7.3 Pfizer Drugs for Retroperitoneal Fibrosis Product and Services
2.7.4 Pfizer Drugs for Retroperitoneal Fibrosis Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8 Merck
2.8.1 Merck Details
2.8.2 Merck Major Business
2.8.3 Merck Drugs for Retroperitoneal Fibrosis Product and Services
2.8.4 Merck Drugs for Retroperitoneal Fibrosis Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9 Bayer
2.9.1 Bayer Details
2.9.2 Bayer Major Business
2.9.3 Bayer Drugs for Retroperitoneal Fibrosis Product and Services
2.9.4 Bayer Drugs for Retroperitoneal Fibrosis Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10 Novartis
2.10.1 Novartis Details
2.10.2 Novartis Major Business
2.10.3 Novartis Drugs for Retroperitoneal Fibrosis Product and Services
2.10.4 Novartis Drugs for Retroperitoneal Fibrosis Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Drugs for Retroperitoneal Fibrosis Breakdown Data by Manufacturer
3.1 Global Drugs for Retroperitoneal Fibrosis Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Drugs for Retroperitoneal Fibrosis Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Drugs for Retroperitoneal Fibrosis
3.4 Market Concentration Rate
3.4.1 Top 3 Drugs for Retroperitoneal Fibrosis Manufacturer Market Share in 2021
3.4.2 Top 6 Drugs for Retroperitoneal Fibrosis Manufacturer Market Share in 2021
3.5 Global Drugs for Retroperitoneal Fibrosis Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Drugs for Retroperitoneal Fibrosis Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Drugs for Retroperitoneal Fibrosis Market Size by Region
4.1.1 Global Drugs for Retroperitoneal Fibrosis Sales in Volume by Region (2017-2028)
4.1.2 Global Drugs for Retroperitoneal Fibrosis Revenue by Region (2017-2028)
4.2 North America Drugs for Retroperitoneal Fibrosis Revenue (2017-2028)
4.3 Europe Drugs for Retroperitoneal Fibrosis Revenue (2017-2028)
4.4 Asia-Pacific Drugs for Retroperitoneal Fibrosis Revenue (2017-2028)
4.5 South America Drugs for Retroperitoneal Fibrosis Revenue (2017-2028)
4.6 Middle East and Africa Drugs for Retroperitoneal Fibrosis Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Drugs for Retroperitoneal Fibrosis Sales in Volume by Type (2017-2028)
5.2 Global Drugs for Retroperitoneal Fibrosis Revenue by Type (2017-2028)
5.3 Global Drugs for Retroperitoneal Fibrosis Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global Drugs for Retroperitoneal Fibrosis Sales in Volume by Application (2017-2028)
6.2 Global Drugs for Retroperitoneal Fibrosis Revenue by Application (2017-2028)
6.3 Global Drugs for Retroperitoneal Fibrosis Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America Drugs for Retroperitoneal Fibrosis Sales by Type (2017-2028)
7.2 North America Drugs for Retroperitoneal Fibrosis Sales by Application (2017-2028)
7.3 North America Drugs for Retroperitoneal Fibrosis Market Size by Country
7.3.1 North America Drugs for Retroperitoneal Fibrosis Sales in Volume by Country (2017-2028)
7.3.2 North America Drugs for Retroperitoneal Fibrosis Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe Drugs for Retroperitoneal Fibrosis Sales by Type (2017-2028)
8.2 Europe Drugs for Retroperitoneal Fibrosis Sales by Application (2017-2028)
8.3 Europe Drugs for Retroperitoneal Fibrosis Market Size by Country
8.3.1 Europe Drugs for Retroperitoneal Fibrosis Sales in Volume by Country (2017-2028)
8.3.2 Europe Drugs for Retroperitoneal Fibrosis Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Drugs for Retroperitoneal Fibrosis Sales by Type (2017-2028)
9.2 Asia-Pacific Drugs for Retroperitoneal Fibrosis Sales by Application (2017-2028)
9.3 Asia-Pacific Drugs for Retroperitoneal Fibrosis Market Size by Region
9.3.1 Asia-Pacific Drugs for Retroperitoneal Fibrosis Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Drugs for Retroperitoneal Fibrosis Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America Drugs for Retroperitoneal Fibrosis Sales by Type (2017-2028)
10.2 South America Drugs for Retroperitoneal Fibrosis Sales by Application (2017-2028)
10.3 South America Drugs for Retroperitoneal Fibrosis Market Size by Country
10.3.1 South America Drugs for Retroperitoneal Fibrosis Sales in Volume by Country (2017-2028)
10.3.2 South America Drugs for Retroperitoneal Fibrosis Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Drugs for Retroperitoneal Fibrosis Sales by Type (2017-2028)
11.2 Middle East & Africa Drugs for Retroperitoneal Fibrosis Sales by Application (2017-2028)
11.3 Middle East & Africa Drugs for Retroperitoneal Fibrosis Market Size by Country
11.3.1 Middle East & Africa Drugs for Retroperitoneal Fibrosis Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Drugs for Retroperitoneal Fibrosis Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Drugs for Retroperitoneal Fibrosis and Key Manufacturers
12.2 Manufacturing Costs Percentage of Drugs for Retroperitoneal Fibrosis
12.3 Drugs for Retroperitoneal Fibrosis Production Process
12.4 Drugs for Retroperitoneal Fibrosis Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Drugs for Retroperitoneal Fibrosis Typical Distributors
13.3 Drugs for Retroperitoneal Fibrosis Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer